Clinical	O
Impact	O
of	O
Atrial	B-DS
Fibrillation	I-DS
in	O
Patients	O
with	O
Pulmonary	B-DS
Hypertension	I-DS

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
DR	O
LJM	O
S	O
.	O

Reda	O
UCH	O
.	O

Performed	O
the	O
experiments	O
:	O
DR	O
LJM	O
S	O
.	O

Reda	O
UCH	O
DS	O
DD	O
.	O

Analyzed	O
the	O
data	O
:	O
DR	O
LJM	O
S	O
.	O

Reda	O
UCH	O
EE	O
S	O
.	O

Rosenkranz	O
RL	O
MW	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
DR	O
LJM	O
S	O
.	O

Reda	O
UCH	O
S	O
.	O

Rosenkranz	O
EE	O
.	O

Wrote	O
the	O
paper	O
:	O
DR	O
LJM	O
MW	O
S	O
.	O

Reda	O
UCH	O
.	O

Background	O

Pulmonary	B-DS
hypertension	I-DS
(	O
PH	B-DS
)	O
is	O
associated	O
with	O
progressive	O
impairment	O
of	O
right	O
ventricular	O
function	O
,	O
reduced	O
exercise	O
capacity	O
and	O
a	O
poor	O
prognosis	O
.	O

Little	O
is	O
known	O
about	O
the	O
prevalence	O
,	O
clinical	O
manifestation	O
and	O
impact	O
of	O
atrial	B-DS
fibrillation	I-DS
(	O
AF	B-DS
)	O
on	O
cardiac	O
function	O
in	O
PH	B-DS
.	O

Methods	O

In	O
a	O
four	O
year	O
single	O
-	O
centre	O
retrospective	O
analysis	O
225	O
patients	O
with	O
confirmed	O
PH	B-DS
of	O
various	O
origins	O
were	O
enrolled	O
to	O
investigate	O
the	O
prevalence	O
of	O
AF	B-DS
,	O
and	O
to	O
assess	O
the	O
clinical	O
manifestation	O
,	O
6	O
-	O
minute	O
walk	O
distance	O
,	O
NT	B-GP
-	I-GP
proBNP	I-GP
levels	O
,	O
echocardiographic	O
parameters	O
and	O
hemodynamics	O
obtained	O
by	O
right	O
heart	O
catheterization	O
in	O
PH	B-DS
with	O
AF	B-DS
.	O

Results	O

AF	B-DS
was	O
prevalent	O
in	O
31	O
.	O
1	O
%.	O

In	O
patients	O
with	O
PH	B-DS
and	O
AF	B-DS
,	O
parameters	O
of	O
clinical	O
deterioration	O
(	O
NYHA	O
/	O
WHO	O
functional	O
class	O
,	O
6	O
-	O
minute	O
walk	O
distance	O
,	O
NT	B-GP
-	I-GP
proBNP	I-GP
levels	O
)	O
and	O
renal	O
function	O
were	O
significantly	O
compromised	O
compared	O
to	O
patients	O
with	O
PH	B-DS
and	O
sinus	O
rhythm	O
(	O
SR	O
).	O

In	O
the	O
total	O
PH	B-DS
cohort	O
and	O
in	O
PH	B-DS
not	O
related	O
to	O
left	O
heart	B-DS
disease	I-DS
occurrence	O
of	O
AF	B-DS
was	O
associated	O
with	O
an	O
increase	O
of	O
right	O
atrial	O
pressure	O
(	O
RAP	O
)	O
and	O
right	B-DS
atrial	I-DS
dilatation	I-DS
.	O

While	O
no	O
direct	O
association	O
was	O
found	O
between	O
pulmonary	O
artery	O
pressure	O
(	O
PAP	O
)	O
and	O
AF	B-DS
in	O
these	O
patients	O
,	O
right	O
ventricular	O
function	O
was	O
reduced	O
in	O
AF	B-DS
,	O
indicating	O
more	O
advanced	O
disease	O
.	O

In	O
PH	B-DS
due	O
to	O
left	B-DS
heart	I-DS
failure	I-DS
the	O
prevalence	O
of	O
AF	B-DS
was	O
particularly	O
high	O
(	O
57	O
.	O
7	O
%	O
vs	O
.	O
23	O
.	O
1	O
%	O
in	O
other	O
forms	O
of	O
PH	B-DS
).	O

In	O
this	O
subgroup	O
,	O
left	B-DS
atrial	I-DS
dilatation	I-DS
,	O
increase	O
of	O
pulmonary	O
capillary	O
wedge	O
pressure	O
,	O
PAP	O
and	O
RAP	O
were	O
more	O
pronounced	O
in	O
AF	B-DS
than	O
in	O
SR	O
,	O
suggesting	O
that	O
more	O
marked	O
backward	O
failure	O
led	O
to	O
AF	B-DS
in	O
this	O
setting	O
.	O

Conclusion	O

PH	B-DS
is	O
associated	O
with	O
increased	O
prevalence	O
of	O
AF	B-DS
.	O

Occurrence	O
of	O
AF	B-DS
in	O
PH	B-DS
indicates	O
clinical	O
deterioration	O
and	O
more	O
advanced	O
disease	O
.	O

Introduction	O

Pulmonary	B-DS
hypertension	I-DS
(	O
PH	B-DS
)	O
–	O
i	O
.	O
e	O
.	O
an	O
elevated	O
mean	O
pulmonary	O
artery	O
pressure	O
(	O
PAP	O
),	O
≥	O
25	O
mmHg	O
at	O
rest	O
–	O
defines	O
a	O
group	O
of	O
diseases	O
characterized	O
by	O
a	O
progressive	O
increase	O
in	O
pulmonary	O
vascular	O
resistance	O
leading	O
to	O
right	B-DS
ventricular	I-DS
failure	I-DS
and	O
premature	O
death	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
3	O
].	O

Based	O
on	O
the	O
pathophysiological	O
mechanisms	O
and	O
etiology	O
,	O
the	O
current	O
clinical	O
classification	O
distinguishes	O
five	O
groups	O
of	O
PH	B-DS
[	O
4	O
].	O

Left	B-DS
heart	I-DS
failure	I-DS
(	O
HF	B-DS
)	O
is	O
one	O
common	O
cause	O
of	O
PH	B-DS
,	O
representing	O
group	O
2	O
of	O
the	O
Dana	O
-	O
Point	O
classification	O
.	O

Left	B-DS
ventricular	I-DS
systolic	I-DS
dysfunction	I-DS
,	O
diastolic	O
dysfunction	O
or	O
valvular	B-DS
disease	I-DS
may	O
all	O
result	O
in	O
elevated	O
PAP	O
.	O

In	O
fact	O
,	O
PH	B-DS
is	O
being	O
found	O
in	O
more	O
than	O
60	O
%	O
of	O
patients	O
with	O
moderate	O
or	O
severe	O
HF	B-DS
[	O
5	O
].	O

However	O
,	O
from	O
a	O
pathophysiological	O
point	O
of	O
view	O
and	O
with	O
regard	O
to	O
therapeutic	O
options	O
,	O
PH	B-DS
due	O
to	O
left	O
heart	B-DS
disease	I-DS
is	O
clearly	O
differentiated	O
from	O
pulmonary	B-DS
arterial	I-DS
hypertension	I-DS
(	O
PAH	B-DS
)	O
and	O
has	O
to	O
be	O
appreciated	O
as	O
a	O
separate	O
entity	O
.	O

At	O
present	O
,	O
targeted	O
PAH	B-DS
therapies	O
are	O
not	O
recommended	O
for	O
this	O
subgroup	O
.	O

Atrial	B-DS
fibrillation	I-DS
(	O
AF	B-DS
)	O
is	O
the	O
most	O
common	O
chronic	B-DS
arrhythmia	I-DS
.	O

Chronic	O
left	B-DS
heart	I-DS
failure	I-DS
and	O
AF	B-DS
often	O
coexist	O
.	O

Both	O
are	O
responsible	O
for	O
increased	O
mortality	O
,	O
more	O
frequent	O
hospitalizations	O
,	O
reduced	O
exercise	O
capacity	O
,	O
decreased	O
quality	O
of	O
life	O
and	O
substantial	O
health	O
care	O
expenditures	O
[	O
6	O
].	O

In	O
addition	O
to	O
merely	O
having	O
risk	O
factors	O
in	O
common	O
,	O
AF	B-DS
and	O
heart	B-DS
failure	I-DS
are	O
believed	O
to	O
directly	O
predispose	O
to	O
each	O
other	O
[	O
7	O
],	O
[	O
8	O
].	O

The	O
risk	O
of	O
developing	O
AF	B-DS
during	O
long	O
-	O
term	O
follow	O
-	O
up	O
appears	O
to	O
be	O
5	O
to	O
10	O
times	O
higher	O
in	O
patients	O
with	O
left	B-DS
heart	I-DS
failure	I-DS
than	O
in	O
healthy	O
persons	O
[	O
9	O
],	O
[	O
10	O
],	O
[	O
11	O
],	O
[	O
12	O
].	O

Some	O
studies	O
have	O
shown	O
that	O
the	O
onset	O
of	O
AF	B-DS
in	O
these	O
patients	O
is	O
associated	O
with	O
clinical	O
and	O
hemodynamic	O
deterioration	O
due	O
to	O
loss	O
of	O
atrial	O
contractility	O
,	O
tachycardia	O
,	O
and	O
lack	O
of	O
atrioventricular	O
synchrony	O
,	O
as	O
well	O
as	O
a	O
worse	O
long	O
-	O
term	O
prognosis	O
[	O
13	O
],	O
[	O
14	O
].	O

Although	O
the	O
association	O
between	O
AF	B-DS
and	O
left	B-DS
heart	I-DS
failure	I-DS
is	O
well	O
documented	O
,	O
the	O
predisposing	O
factors	O
for	O
developing	O
AF	B-DS
in	O
this	O
setting	O
are	O
not	O
fully	O
understood	O
.	O

Moreover	O
,	O
the	O
prevalence	O
of	O
AF	B-DS
in	O
PH	B-DS
with	O
or	O
without	O
compromised	O
right	O
ventricular	O
function	O
has	O
not	O
been	O
defined	O
.	O

Learning	O
more	O
about	O
which	O
types	O
of	O
patients	O
with	O
PH	B-DS
develop	O
AF	B-DS
may	O
yield	O
important	O
insights	O
into	O
the	O
pathogenesis	O
of	O
AF	B-DS
in	O
this	O
condition	O
,	O
and	O
importantly	O
may	O
help	O
guide	O
clinicians	O
in	O
the	O
monitoring	O
,	O
evaluation	O
,	O
and	O
management	O
of	O
these	O
patients	O
.	O

Methods	O

Study	O
participants	O

The	O
study	O
was	O
performed	O
according	O
to	O
good	O
clinical	O
practice	O
and	O
in	O
compliance	O
with	O
the	O
Helsinki	O
declaration	O
.	O

Individual	O
patient	O
were	O
not	O
identified	O
.	O

An	O
individual	O
written	O
consent	O
was	O
obtained	O
by	O
every	O
patient	O
,	O
which	O
is	O
usually	O
performed	O
due	O
to	O
quality	O
management	O
issues	O
in	O
our	O
hospital	O
.	O

The	O
study	O
and	O
study	O
design	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
.	O

The	O
study	O
cohort	O
comprised	O
225	O
consecutive	O
patients	O
with	O
confirmed	O
diagnosis	O
of	O
PH	B-DS
referred	O
to	O
a	O
single	O
-	O
centre	O
between	O
October	O
01	O
,	O
2006	O
and	O
March	O
31	O
,	O
2010	O
.	O

In	O
all	O
eligible	O
patients	O
,	O
exact	O
classification	O
of	O
PH	B-DS
into	O
one	O
of	O
the	O
five	O
groups	O
according	O
to	O
the	O
Dana	O
-	O
Point	O
classification	O
was	O
performed	O
[	O
4	O
],	O
and	O
information	O
about	O
the	O
clinical	O
severity	O
(	O
NYHA	O
/	O
WHO	O
functional	O
class	O
),	O
medication	O
,	O
concomitant	O
diseases	O
,	O
6	O
-	O
minute	O
walk	O
distance	O
and	O
N	B-GP
-	I-GP
terminal	I-GP
pro	I-GP
-	I-GP
brain	I-GP
natriuretic	I-GP
peptide	I-GP
(	O
NT	B-GP
-	I-GP
proBNP	I-GP
)	O
levels	O
were	O
obtained	O
from	O
the	O
University	O
Patient	O
Database	O
.	O

Furthermore	O
,	O
if	O
available	O
,	O
echocardiography	O
was	O
analyzed	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
1	O
.	O
patients	O
with	O
PH	B-DS
and	O
sinus	O
rhythm	O
(	O
PH	B-DS
-	O
SR	O
)	O
and	O
2	O
.	O
patients	O
with	O
PH	B-DS
and	O
atrial	B-DS
fibrillation	I-DS
(	O
PH	B-DS
-	O
AF	B-DS
).	O

Given	O
distinct	O
cardiac	O
pathomechanisms	O
,	O
subgroup	O
analysis	O
was	O
performed	O
in	O
patients	O
with	O
PH	B-DS
due	O
to	O
left	B-DS
heart	I-DS
failure	I-DS
(	O
a	O
.	O

PH	B-DS
-	O
HF	B-DS
SR	O
and	O
b	O
.	O

PH	B-DS
-	O
HF	B-DS
AF	B-DS
)	O
and	O
PH	B-DS
due	O
to	O
any	O
other	O
cause	O
(	O
c	O
.	O

PH	B-DS
-	O
nonHF	O
SR	O
and	O
d	O
.	O

PH	B-DS
-	O
nonHF	O
AF	B-DS
).	O

Definition	O
of	O
prevalent	O
AF	B-DS

“	O
Prevalent	O
AF	B-DS
”	O
was	O
defined	O
as	O
the	O
presence	O
of	O
AF	B-DS
on	O
electrocardiogram	O
during	O
the	O
index	O
hospitalization	O
and	O
/	O
or	O
as	O
indicated	O
by	O
a	O
diagnosis	O
found	O
in	O
medical	O
records	O
,	O
the	O
hospitalization	O
database	O
,	O
or	O
ambulatory	O
visit	O
databases	O
.	O
“	O
Electrocardiographic	O
AF	B-DS
”	O
was	O
defined	O
as	O
the	O
presence	O
of	O
an	O
irregular	O
rhythm	O
with	O
fibrillatory	O
waves	O
and	O
no	O
defined	O
P	O
-	O
waves	O
[	O
9	O
].	O

Diagnoses	O
were	O
based	O
on	O
physician	O
-	O
assigned	O
diagnoses	O
in	O
the	O
medical	O
records	O
and	O
/	O
or	O
the	O
presence	O
of	O
corresponding	O
ICD	O
-	O
9	O
-	O
CM	O
codes	O
for	O
AF	B-DS
(	O
427	O
.	O
31	O
)	O
in	O
the	O
hospital	O
discharge	O
or	O
ambulatory	O
visit	O
clinical	O
databases	O
.	O

Atrial	B-DS
fibrillation	I-DS
was	O
sub	O
-	O
classified	O
into	O
paroxysmal	B-DS
AF	I-DS
or	O
chronic	B-DS
AF	I-DS
(	O
persistent	O
or	O
permanent	O
)	O
according	O
to	O
international	O
guidelines	O
.	O

Etiology	O
and	O
severity	O
of	O
PH	B-DS

Patients	O
were	O
classified	O
according	O
to	O
the	O
Dana	O
Point	O
classification	O
of	O
PH	B-DS
,	O
and	O
clinical	O
severity	O
was	O
assessed	O
according	O
to	O
the	O
WHO	O
functional	O
classes	O
for	O
PH	B-DS
[	O
4	O
].	O

In	O
PH	B-DS
due	O
to	O
left	B-DS
heart	I-DS
failure	I-DS
with	O
reduced	O
ejection	O
fraction	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
was	O
defined	O
as	O
lower	O
than	O
40	O
%	O
(	O
as	O
assessed	O
by	O
echocardiography	O
,	O
biplane	O
Simpson	O
method	O
in	O
apical	O
four	O
chamber	O
view	O
).	O

Heart	B-DS
failure	I-DS
with	O
preserved	O
ejection	O
fraction	O
was	O
diagnosed	O
following	O
the	O
consensus	O
statement	O
of	O
the	O
Association	O
of	O
the	O
European	O
Society	O
of	O
Cardiology	O
[	O
15	O
].	O

Valvular	B-DS
disease	I-DS
was	O
defined	O
as	O
mitral	O
and	O
/	O
or	O
aortic	B-DS
stenosis	I-DS
or	O
insufficiency	O
or	O
valve	O
repair	O
.	O

Six	O
-	O
minute	O
walk	O
testing	O

Patients	O
were	O
instructed	O
to	O
walk	O
down	O
a	O
100	O
-	O
foot	O
corridor	O
at	O
their	O
own	O
pace	O
,	O
attempting	O
to	O
cover	O
as	O
much	O
ground	O
as	O
possible	O
.	O

At	O
the	O
end	O
of	O
the	O
six	O
minute	O
interval	O
the	O
total	O
distance	O
was	O
determined	O
.	O

The	O
test	O
was	O
performed	O
by	O
personnel	O
that	O
had	O
been	O
trained	O
according	O
to	O
the	O
current	O
ATS	O
consensus	O
statement	O
on	O
six	O
-	O
minute	O
walk	O
testing	O
[	O
16	O
].	O

Forty	O
-	O
two	O
patients	O
were	O
excluded	O
from	O
testing	O
due	O
to	O
disability	O
of	O
movement	O
.	O

Clinical	O
laboratory	O
parameters	O

N	B-GP
-	I-GP
terminal	I-GP
pro	I-GP
-	I-GP
brain	I-GP
natriuretic	I-GP
peptide	I-GP
(	O
NT	B-GP
-	I-GP
proBNP	I-GP
)	O
was	O
measured	O
in	O
every	O
patient	O
as	O
a	O
marker	O
of	O
heart	B-DS
failure	I-DS
known	O
to	O
correlate	O
with	O
survival	O
and	O
the	O
severity	O
of	O
disease	O
in	O
both	O
left	O
and	O
right	B-DS
heart	I-DS
failure	I-DS
.	O

Additionally	O
,	O
renal	O
function	O
parameters	O
,	O
i	O
.	O
e	O
.	O
creatinine	O
,	O
urea	O
nitrogen	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
,	O
using	O
the	O
MDRD	O
equation	O
[	O
17	O
])	O
were	O
determined	O
.	O

Echocardiography	O

All	O
transthoracic	O
echocardiographic	O
studies	O
were	O
obtained	O
by	O
experienced	O
investigators	O
using	O
a	O
Philips	O
iE	O
33	O
echocardiography	O
system	O
(	O
Philips	O
,	O
Hamburg	O
,	O
Germany	O
).	O

Left	O
atrial	O
diameter	O
(	O
edge	O
-	O
to	O
-	O
edge	O
method	O
,	O
parasternal	O
view	O
),	O
right	O
atrial	O
area	O
(	O
measured	O
at	O
end	O
-	O
systole	O
in	O
the	O
apical	O
four	O
chamber	O
view	O
),	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
biplane	O
Simpson	O
method	O
),	O
Tricuspid	O
Annular	O
Plane	O
Systolic	O
Excursion	O
(	O
TAPSE	O
)	O
and	O
pulmonary	O
artery	O
systolic	O
pressure	O
were	O
recorded	O
according	O
to	O
current	O
recommendations	O
[	O
18	O
].	O

Only	O
complete	O
datasets	O
were	O
included	O
in	O
the	O
statistical	O
analysis	O
.	O

Right	O
heart	O
catheterization	O

Right	O
heart	O
catheterization	O
was	O
performed	O
via	O
the	O
femoral	O
vein	O
using	O
a	O
balloon	O
flotation	O
catheter	O
(	O
PWP	O
catheter	O
,	O
Medtronic	O
,	O
Minneapolis	O
,	O
USA	O
).	O

Fluoroscopic	O
guidance	O
was	O
used	O
to	O
cannulate	O
the	O
pulmonary	O
artery	O
and	O
obtain	O
pulmonary	O
capillary	O
wedge	O
position	O
.	O

Right	O
heart	O
catheterization	O
studies	O
were	O
analyzed	O
for	O
systolic	O
and	O
mean	O
pulmonary	O
arterial	O
pressure	O
,	O
pulmonary	O
capillary	O
wedge	O
pressure	O
(	O
PCWP	O
),	O
right	O
atrial	O
pressure	O
and	O
pulmonary	O
vascular	O
resistance	O
.	O

Cardiac	O
output	O
was	O
estimated	O
using	O
the	O
Fick	O
technique	O
.	O

Echocardiograms	O
and	O
right	O
heart	O
catheterization	O
were	O
performed	O
at	O
the	O
same	O
time	O
.	O

Statistical	O
analysis	O

Statistical	O
analyses	O
were	O
performed	O
using	O
PASW	O
statistics	O
18	O
software	O
(	O
SPSS	O
,	O
Chicago	O
,	O
USA	O
).	O

All	O
variables	O
were	O
tested	O
for	O
normal	O
distribution	O
with	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
.	O

The	O
results	O
are	O
given	O
as	O
mean	O
±	O
standard	O
error	O
of	O
mean	O
(	O
SEM	O
).	O

All	O
groups	O
and	O
subgroups	O
were	O
compared	O
for	O
PH	B-DS
classification	O
,	O
clinical	O
manifestation	O
,	O
6	O
-	O
minute	O
-	O
walk	O
-	O
testing	O
,	O
laboratory	O
parameters	O
,	O
data	O
of	O
echocardiography	O
and	O
right	O
heart	O
catheterization	O
.	O

Differences	O
between	O
groups	O
and	O
subgroups	O
were	O
evaluated	O
by	O
chi	O
-	O
square	O
-	O
testing	O
for	O
discrete	O
variables	O
and	O
student	O
-	O
t	O
test	O
for	O
continuous	O
variables	O
.	O

For	O
ordinal	O
data	O
Mann	O
-	O
Whitney	O
-	O
U	O
test	O
was	O
used	O
.	O

A	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

Results	O

Baseline	O
characteristics	O
and	O
prevalence	O
of	O
AF	B-DS

A	O
total	O
of	O
225	O
patients	O
with	O
PH	B-DS
were	O
analyzed	O
in	O
this	O
retrospective	O
study	O
.	O

Seventy	O
patients	O
(	O
31	O
.	O
1	O
%)	O
of	O
the	O
total	O
study	O
cohort	O
had	O
evidence	O
of	O
AF	B-DS
.	O

In	O
patients	O
with	O
AF	B-DS
,	O
41	O
.	O
3	O
%	O
had	O
paroxysmal	B-DS
AF	I-DS
,	O
whereas	O
58	O
.	O
7	O
%	O
presented	O
with	O
chronic	B-DS
AF	I-DS
.	O

The	O
demographic	O
variables	O
of	O
the	O
individual	O
groups	O
with	O
and	O
without	O
AF	B-DS
are	O
shown	O
in	O
table	O
1	O
.	O

Patients	O
in	O
both	O
groups	O
were	O
predominantly	O
female	O
.	O

Mean	O
age	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
PH	B-DS
-	O
SR	O
and	O
PH	B-DS
-	O
AF	B-DS
group	O
.	O

Patients	O
'	O
Characteristics	O
.	O

PH	B-DS
-	O
SR	O
(	O
n	O
=	O
155	O
)	O

PH	B-DS
-	O
AF	B-DS
(	O
n	O
=	O
70	O
)	O

Characteristic	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

Age	O

155	O

62	O
.	O
9	O
±	O
1	O
.	O
2	O

70	O

71	O
.	O
2	O
±	O
1	O
.	O
1	O

Male	O

58	O

37	O
.	O
4	O
%	O

25	O

35	O
.	O
7	O
%	O

Female	O

97	O

62	O
.	O
6	O
%	O

45	O

64	O
.	O
3	O
%	O

Mean	O
heart	O
rate	O
(	O
bpm	O
)	O

155	O

79	O
.	O
5	O
±	O
1	O
.	O
3	O

70	O

74	O
.	O
6	O
±	O
1	O
.	O
9	O

WHO	O
group	O
|	O
PH	B-DS
subgroup	O

Pulmonary	B-DS
arterial	I-DS
hypertension	I-DS

78	O

50	O
.	O
3	O
%	O

32	O

45	O
.	O
7	O
%	O

Idiopathic	O

31	O

20	O
.	O
0	O
%	O

24	O

34	O
.	O
3	O
%*	O

Heritable	O

2	O

1	O
.	O
3	O
%	O

0	O

0	O
%	O

Drug	O
-	O
and	O
toxin	O
-	O
induced	O

4	O

2	O
.	O
6	O
%	O

0	O

0	O
%	O

Associated	O
with	O

Congenital	O
heart	B-DS
disease	I-DS

6	O

3	O
.	O
9	O
%	O

3	O

4	O
.	O
3	O
%	O

HIV	O
infection	O

3	O

1	O
.	O
9	O
%	O

0	O

0	O
%	O

Connective	O
tissue	O
disease	O

32	O

20	O
.	O
6	O
%	O

3	O

4	O
.	O
3	O
%*	O

Portal	O
hypertension	O

0	O

0	O
%	O

2	O

2	O
.	O
9	O
%	O

Veno	O
-	O
occlusive	O
disease	O

0	O

0	O
%	O

0	O

0	O
%	O

Pulmonary	B-DS
hypertension	I-DS
due	O
to	O
left	B-DS
heart	I-DS
failure	I-DS

22	O

14	O
.	O
2	O
%	O

30	O

42	O
.	O
9	O
%*	O

Systolic	B-DS
dysfunction	I-DS

6	O

3	O
.	O
9	O
%	O

10	O

14	O
.	O
3	O
%*	O

Diastolic	O
dysfunction	O

13	O

8	O
.	O
4	O
%	O

17	O

24	O
.	O
3	O
%*	O

Valvular	B-DS
disease	I-DS

3	O

1	O
.	O
9	O
%	O

3	O

4	O
.	O
3	O
%	O

Pulmonary	B-DS
hypertension	I-DS
due	O
to	O
pulmonary	B-DS
disease	I-DS

21	O

13	O
.	O
5	O
%	O

5	O

7	O
.	O
1	O
%	O

Chronic	O
obstructive	O
pulmonary	B-DS
disease	I-DS

7	O

4	O
.	O
5	O
%	O

3	O

4	O
.	O
3	O
%	O

Interstitial	O
lung	O
disease	O

14	O

9	O
.	O
0	O
%	O

2	O

2	O
.	O
9	O
%	O

Chronic	B-DS
thromboembolic	I-DS
pulmonary	I-DS
hypertension	I-DS

31	O

20	O
.	O
0	O
%	O

2	O

2	O
.	O
9	O
%*	O

Others	O

3	O

1	O
.	O
9	O
%	O

1	O

1	O
.	O
4	O
%	O

Medication	O

Phosphodiesterase	B-GP
-	I-GP
5	I-GP
-	O
inhibitor	O

51	O

32	O
.	O
9	O
%	O

31	O

44	O
.	O
3	O
%	O

Endothelin	O
-	O
1	O
antagonist	O

47	O

30	O
.	O
3	O
%	O

15	O

21	O
.	O
4	O
%	O

Prostacyclin	O

7	O

4	O
.	O
5	O
%	O

3	O

4	O
.	O
3	O
%	O

Calcium	O
channel	O
blockers	O

29	O

18	O
.	O
7	O
%	O

17	O

24	O
.	O
3	O
%	O

Betablocker	O

65	O

41	O
.	O
9	O
%	O

51	O

72	O
.	O
9	O
%*	O

Digitalis	O

8	O

5	O
.	O
2	O
%	O

26	O

37	O
.	O
1	O
%*	O

Amiodarone	O

1	O

0	O
.	O
6	O
%	O

7	O

10	O
.	O
0	O
%*	O

Sotalol	O

2	O

1	O
.	O
3	O
%	O

1	O

1	O
.	O
4	O
%	O

Diuretics	O

112	O

72	O
.	O
3	O
%	O

65	O

92	O
.	O
9	O
%*	O

Angiotensin	B-GP
receptor	I-GP
blockers	O
/	O
AT	B-GP
-	I-GP
1	I-GP
antagonist	O

82	O

52	O
.	O
9	O
%	O

42	O

60	O
.	O
0	O
%	O

Cumarine	O

61	O

39	O
.	O
4	O
%	O

55	O

78	O
.	O
6	O
%*	O

Acetylsalicylic	O
acid	O

49	O

31	O
.	O
6	O
%	O

11	O

15	O
.	O
7	O
%*	O

Clopidogrel	O

10	O

6	O
.	O
5	O
%	O

4	O

5	O
.	O
7	O
%	O

Statins	O

41	O

26	O
.	O
5	O
%	O

27	O

38	O
.	O
6	O
%	O

Nitrates	O

11	O

7	O
.	O
1	O
%	O

3	O

4	O
.	O
3	O
%	O

Concomitant	O
disease	O

Coronary	O
artery	O
disease	O

39	O

25	O
.	O
2	O
%	O

19	O

27	O
.	O
1	O
%	O

Myocardial	O
infarction	O

9	O

5	O
.	O
8	O
%	O

8	O

11	O
.	O
4	O
%	O

Coronary	O
artery	O
bypass	O
graft	O

5	O

3	O
.	O
2	O
%	O

7	O

10	O
.	O
0	O
%	O

Dilated	O
cardiomyopathy	O

3	O

1	O
.	O
9	O
%	O

7	O

10	O
.	O
0	O
%*	O

Valvular	B-DS
disease	I-DS

14	O

9	O
.	O
0	O
%	O

20	O

28	O
.	O
6	O
%*	O

Arterial	O
hypertension	O

75	O

48	O
.	O
4	O
%	O

45	O

64	O
.	O
3	O
%*	O

Pulmonary	B-DS
disease	I-DS

97	O

62	O
.	O
6	O
%	O

27	O

38	O
.	O
6	O
%*	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
.	O

When	O
evaluating	O
the	O
relative	O
percentage	O
of	O
the	O
distinct	O
etiologies	O
of	O
PH	B-DS
according	O
to	O
the	O
Dana	O
Point	O
classification	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
versus	O
PH	B-DS
-	O
SR	O
group	O
,	O
we	O
obtained	O
no	O
significant	O
difference	O
for	O
PH	B-DS
due	O
to	O
pulmonary	B-DS
disease	I-DS
.	O

However	O
,	O
PH	B-DS
due	O
to	O
left	B-DS
heart	I-DS
failure	I-DS
(	O
PH	B-DS
-	O
HF	B-DS
)	O
was	O
markedly	O
more	O
common	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
(	O
PH	B-DS
-	O
AF	B-DS
42	O
.	O
9	O
%	O
vs	O
.	O
PH	B-DS
-	O
SR	O
14	O
.	O
2	O
%,	O
p	O
<	O
0	O
.	O
05	O
).	O

This	O
observation	O
was	O
consistent	O
for	O
all	O
causes	O
of	O
left	B-DS
heart	I-DS
failure	I-DS
,	O
though	O
for	O
valvular	B-DS
disease	I-DS
the	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
most	O
likely	O
due	O
to	O
the	O
limited	O
number	O
of	O
patients	O
in	O
this	O
subgroup	O
(	O
table	O
1	O
).	O

Notably	O
,	O
57	O
.	O
7	O
%	O
of	O
all	O
patients	O
with	O
PH	B-DS
-	O
HF	B-DS
presented	O
with	O
AF	B-DS
,	O
compared	O
to	O
23	O
.	O
1	O
%	O
in	O
the	O
PH	B-DS
-	O
nonHF	O
group	O
.	O

Conversely	O
,	O
the	O
relative	O
percentage	O
of	O
chronic	B-DS
thromboembolic	I-DS
pulmonary	I-DS
hypertension	I-DS
(	O
CTEPH	B-DS
)	O
was	O
higher	O
in	O
the	O
PH	B-DS
population	O
with	O
SR	O
(	O
PH	B-DS
-	O
SR	O
20	O
.	O
0	O
%	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
2	O
.	O
9	O
%,	O
p	O
<	O
0	O
.	O
05	O
).	O

While	O
we	O
observed	O
a	O
similar	O
percentage	O
of	O
pulmonary	B-DS
arterial	I-DS
hypertension	I-DS
(	O
PAH	B-DS
)	O
per	O
se	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
and	O
PH	B-DS
-	O
SR	O
group	O
(	O
45	O
.	O
7	O
%	O
vs	O
.	O
50	O
.	O
3	O
%,	O
n	O
.	O
s	O
.),	O
idiopathic	O
PAH	B-DS
was	O
more	O
frequent	O
in	O
those	O
with	O
AF	B-DS
(	O
PH	B-DS
-	O
AF	B-DS
34	O
.	O
3	O
%	O
vs	O
.	O
PH	B-DS
-	O
SR	O
20	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
05	O
),	O
reflecting	O
an	O
AF	B-DS
prevalence	O
of	O
43	O
.	O
6	O
%	O
in	O
this	O
subpopulation	O
.	O

A	O
comparison	O
of	O
patients	O
with	O
paroxysmal	O
(	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
)	O
and	O
chronic	O
(	O
PH	B-DS
-	O
AF	B-DS
chronic	O
)	O
AF	B-DS
in	O
PH	B-DS
revealed	O
chronic	B-DS
AF	I-DS
to	O
be	O
associate	O
with	O
PH	B-DS
due	O
to	O
pulmonary	B-DS
disease	I-DS
(	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
0	O
%	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
chronic	O
11	O
.	O
9	O
%,	O
p	O
<	O
0	O
.	O
05	O
).	O

Moreover	O
,	O
PH	B-DS
due	O
to	O
systolic	B-DS
dysfunction	I-DS
was	O
associated	O
with	O
chronic	B-DS
AF	I-DS
,	O
while	O
diastolic	O
dysfunction	O
was	O
related	O
to	O
paroxysmal	B-DS
AF	I-DS
(	O
systolic	B-DS
dysfunction	I-DS
:	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
3	O
.	O
6	O
%	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
chronic	O
21	O
.	O
4	O
%,	O
p	O
<	O
0	O
.	O
05	O
;	O
diastolic	O
dysfunction	O
:	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
32	O
.	O
1	O
%	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
chronic	O
19	O
.	O
0	O
%,	O
p	O
<	O
0	O
.	O
05	O
).	O

Targeted	O
therapy	O
for	O
PAH	B-DS
such	O
as	O
prostacyclin	O
analogues	O
,	O
endothelin	B-GP
receptor	I-GP
antagonists	O
and	O
phosphodiesterase	B-GP
-	I-GP
5	I-GP
inhibitors	O
were	O
equally	O
prescribed	O
in	O
PAH	B-DS
patients	O
with	O
and	O
without	O
AF	B-DS
.	O

Expectedly	O
,	O
treatment	O
for	O
AF	B-DS
,	O
i	O
.	O
e	O
.	O
betablockers	O
,	O
digitalis	O
,	O
amiodarone	O
and	O
cumarine	O
was	O
more	O
common	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
.	O

Notably	O
,	O
patients	O
with	O
PH	B-DS
-	O
AF	B-DS
more	O
often	O
received	O
diuretics	O
indicating	O
more	O
advanced	O
heart	B-DS
failure	I-DS
.	O

Clinical	O
presentation	O
of	O
patients	O
with	O
AF	B-DS
in	O
PH	B-DS

Thus	O
far	O
,	O
clinical	O
manifestation	O
of	O
AF	B-DS
in	O
PH	B-DS
has	O
not	O
been	O
analyzed	O
systematically	O
.	O

Therefore	O
,	O
we	O
evaluated	O
functional	O
class	O
,	O
exercise	O
capacity	O
,	O
and	O
laboratory	O
parameters	O
indicative	O
of	O
hemodynamic	O
status	O
in	O
this	O
population	O
.	O

The	O
clinical	O
condition	O
in	O
patients	O
with	O
AF	B-DS
in	O
PH	B-DS
was	O
more	O
severe	O
than	O
in	O
patients	O
without	O
AF	B-DS
,	O
as	O
indicated	O
by	O
the	O
NYHA	O
/	O
WHO	O
functional	O
class	O
(	O
table	O
2	O
).	O

Consistently	O
,	O
the	O
6	O
-	O
minute	O
walk	O
distance	O
was	O
significantly	O
shorter	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
(	O
PH	B-DS
-	O
SR	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
:	O
355	O
.	O
55	O
±	O
9	O
.	O
86	O
m	O
,	O
n	O
=	O
130	O
vs	O
.	O
321	O
.	O
98	O
±	O
14	O
.	O
1	O
m	O
,	O
n	O
=	O
53	O
;	O
p	O
<	O
0	O
.	O
05	O
,	O
figure	O
1	O
).	O

Moreover	O
,	O
in	O
patients	O
with	O
AF	B-DS
,	O
the	O
elevation	O
of	O
NT	B-GP
-	I-GP
proBNP	I-GP
serum	O
levels	O
was	O
more	O
pronounced	O
(	O
PH	B-DS
-	O
SR	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
:	O
2128	O
.	O
88	O
±	O
429	O
.	O
97	O
ng	O
/	O
l	O
,	O
n	O
=	O
155	O
vs	O
.	O
3252	O
.	O
79	O
±	O
401	O
.	O
76	O
ng	O
/	O
l	O
,	O
n	O
=	O
70	O
;	O
p	O
<	O
0	O
.	O
05	O
,	O
figure	O
1	O
).	O

Laboratory	O
parameters	O
and	O
exercise	O
capacity	O
in	O
PH	B-DS
with	O
and	O
without	O
AF	B-DS
.	O

NT	B-GP
-	I-GP
pro	I-GP
-	I-GP
BNP	I-GP
,	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
),	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
and	O
6	O
-	O
minute	O
walk	O
distance	O
of	O
patients	O
with	O
PH	B-DS
were	O
compared	O
in	O
those	O
with	O
AF	B-DS
(	O
PH	B-DS
-	O
AF	B-DS
)	O
and	O
SR	O
(	O
PH	B-DS
-	O
SR	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Error	O
bars	O
representing	O
standard	O
error	O
of	O
mean	O
.	O

Effect	O
of	O
AF	B-DS
on	O
NYHA	O
class	O
and	O
renal	O
function	O
in	O
PH	B-DS
.	O

PH	B-DS
-	O
SR	O

PH	B-DS
-	O
AF	B-DS

NYHA	O
classification	O

n	O

%	O

n	O

%	O

NYHA	O
I	O

2	O

1	O
.	O
3	O
%	O

0	O

0	O
%#	O

NYHA	O
II	O

52	O

33	O
.	O
5	O
%	O

17	O

24	O
.	O
3	O
%#	O

NYHA	O
III	O

98	O

63	O
.	O
2	O
%	O

51	O

72	O
.	O
9	O
%#	O

NYHA	O
IV	O

3	O

1	O
.	O
9	O
%	O

2	O

2	O
.	O
9	O
%#	O

Renal	O
function	O

CKD	B-DS
class	O
I	O

31	O

20	O
.	O
0	O
%	O

3	O

4	O
.	O
3	O
%#	O

CKD	B-DS
class	O
II	O

62	O

40	O
.	O
0	O
%	O

23	O

32	O
.	O
9	O
%#	O

CKD	B-DS
class	O
III	O

55	O

35	O
.	O
5	O
%	O

35	O

50	O
.	O
0	O
%#	O

CKD	B-DS
class	O
IV	O

6	O

3	O
.	O
9	O
%	O

8	O

11	O
.	O
4	O
%#	O

CKD	B-DS
class	O
V	O

1	O

0	O
.	O
6	O
%	O

1	O

1	O
.	O
4	O
%#	O

CKD	B-DS
=	O
Chronic	B-DS
kidney	I-DS
disease	I-DS
classification	O
.	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
.	O

Given	O
that	O
renal	B-DS
failure	I-DS
was	O
shown	O
to	O
correlate	O
with	O
reduced	O
survival	O
and	O
clinical	O
deterioration	O
,	O
standard	O
parameters	O
of	O
renal	O
function	O
(	O
creatinine	O
,	O
urea	O
nitrogen	O
,	O
eGFR	O
)	O
and	O
chronic	B-DS
renal	I-DS
failure	I-DS
classification	O
were	O
analyzed	O
.	O

As	O
shown	O
in	O
figure	O
1	O
,	O
AF	B-DS
was	O
associated	O
with	O
impaired	B-DS
renal	I-DS
function	I-DS
,	O
reflected	O
by	O
a	O
significant	O
increase	O
of	O
creatinine	O
and	O
urea	O
nitrogen	O
in	O
patients	O
suffering	O
from	O
AF	B-DS
compared	O
to	O
those	O
without	O
AF	B-DS
(	O
PH	B-DS
-	O
SR	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
:	O
1	O
.	O
07	O
±	O
0	O
.	O
03	O
mg	O
/	O
dl	O
,	O
n	O
=	O
154	O
vs	O
.	O
1	O
.	O
37	O
±	O
0	O
.	O
11	O
mg	O
/	O
dl	O
,	O
n	O
=	O
73	O
;	O
49	O
.	O
17	O
±	O
1	O
.	O
97	O
mg	O
/	O
dl	O
,	O
n	O
=	O
154	O
vs	O
.	O
72	O
.	O
61	O
±	O
5	O
.	O
44	O
mg	O
/	O
dl	O
,	O
n	O
=	O
69	O
;	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
a	O
reduced	O
eGFR	O
(	O
PH	B-DS
-	O
SR	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
:	O
69	O
.	O
68	O
±	O
2	O
.	O
11	O
ml	O
/	O
min	O
,	O
n	O
=	O
154	O
vs	O
.	O
54	O
.	O
96	O
±	O
2	O
.	O
65	O
ml	O
/	O
min	O
,	O
n	O
=	O
69	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

Accordingly	O
,	O
patients	O
with	O
AF	B-DS
in	O
PH	B-DS
were	O
found	O
to	O
be	O
in	O
more	O
severe	O
stages	O
of	O
chronic	B-DS
renal	I-DS
failure	I-DS
(	O
table	O
2	O
).	O

Hemodynamic	O
parameters	O
in	O
PH	B-DS
with	O
AF	B-DS

Cardiac	O
function	O
and	O
hemodynamic	O
data	O
were	O
evaluated	O
by	O
echocardiography	O
and	O
right	O
heart	O
catheterization	O
(	O
table	O
3	O
).	O

Expectedly	O
,	O
left	O
atrial	O
diameter	O
was	O
significantly	O
larger	O
,	O
pulmonary	O
capillary	O
wedge	O
pressure	O
(	O
PCWP	O
)	O
was	O
higher	O
(	O
figure	O
2	O
,	O
table	O
3	O
),	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
was	O
reduced	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
,	O
reflecting	O
the	O
marked	O
fraction	O
of	O
PH	B-DS
due	O
to	O
left	O
heart	B-DS
disease	I-DS
.	O

Hemodynamic	O
parameters	O
associated	O
with	O
AF	B-DS
in	O
PH	B-DS
.	O

Left	O
atrial	O
(	O
LA	O
)	O
diameter	O
and	O
right	O
atrial	O
(	O
RA	O
)	O
area	O
were	O
measured	O
by	O
echocardiography	O
in	O
PH	B-DS
-	O
AF	B-DS
compared	O
to	O
PH	B-DS
-	O
SR	O
.	O

PCWP	O
and	O
mean	O
right	O
atrial	O
pressure	O
(	O
RAPmean	O
)	O
were	O
obtained	O
by	O
right	O
heart	O
catheterization	O
in	O
the	O
presence	O
(	O
PH	B-DS
-	O
AF	B-DS
)	O
or	O
absence	O
(	O
PH	B-DS
-	O
SR	O
)	O
of	O
AF	B-DS
in	O
patients	O
with	O
PH	B-DS
.	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Effect	O
of	O
AF	B-DS
on	O
hemodynamic	O
parameters	O
in	O
PH	B-DS
.	O

PH	B-DS
-	O
SR	O

PH	B-DS
-	O
AF	B-DS

Echocardiography	O

n	O

Mean	O
±	O
SEM	O

n	O

Mean	O
±	O
SEM	O

Left	O
atrial	O
diameter	O
[	O
mm	O
]	O

154	O

37	O
.	O
09	O
±	O
0	O
.	O
64	O

69	O

46	O
.	O
16	O
±	O
1	O
.	O
28	O
*	O

Right	O
atrial	O
area	O
[	O
mm2	O
]	O

154	O

23	O
.	O
15	O
±	O
0	O
.	O
62	O

69	O

28	O
.	O
59	O
±	O
1	O
.	O
19	O
*	O

TAPSE	O
[	O
mm	O
]	O

154	O

20	O
.	O
97	O
±	O
0	O
.	O
48	O

69	O

18	O
.	O
07	O
±	O
0	O
.	O
68	O
*	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

154	O

64	O
.	O
59	O
±	O
1	O
.	O
82	O

69	O

60	O
.	O
10	O
±	O
2	O
.	O
18	O

Left	O
ventricular	O
ejection	O
fraction	O
[%]	O

154	O

63	O
.	O
81	O
±	O
0	O
.	O
55	O

69	O

59	O
.	O
84	O
±	O
1	O
.	O
52	O
*	O

Right	O
heart	O
catheterization	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

155	O

65	O
.	O
00	O
±	O
1	O
.	O
86	O

70	O

67	O
.	O
51	O
±	O
2	O
.	O
34	O

Mean	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

155	O

40	O
.	O
25	O
±	O
1	O
.	O
12	O

70	O

40	O
.	O
80	O
±	O
1	O
.	O
56	O

Mean	O
right	O
atrial	O
pressure	O
[	O
mmHg	O
]	O

135	O

9	O
.	O
4	O
±	O
0	O
.	O
43	O

61	O

12	O
.	O
85	O
±	O
0	O
.	O
86	O
*	O

PCWP	O
[	O
mmHg	O
]	O

155	O

11	O
.	O
96	O
±	O
0	O
.	O
38	O

70	O

16	O
.	O
50	O
±	O
0	O
.	O
90	O
*	O

Pulmonary	O
vascular	O
resistance	O
[	O
Wood	O
units	O
]	O

146	O

7	O
.	O
29	O
±	O
0	O
.	O
42	O

66	O

6	O
.	O
45	O
±	O
0	O
.	O
54	O

Cardiac	O
output	O
[	O
l	O
/	O
min	O
]	O

127	O

4	O
.	O
36	O
±	O
0	O
.	O
12	O

47	O

3	O
.	O
91	O
±	O
0	O
.	O
16	O
*	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
.	O

Notably	O
,	O
systolic	O
and	O
mean	O
pulmonary	O
artery	O
pressures	O
showed	O
no	O
differences	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
compared	O
to	O
the	O
PH	B-DS
-	O
SR	O
group	O
,	O
implicating	O
that	O
pulmonary	O
artery	O
pressure	O
per	O
se	O
has	O
no	O
direct	O
effect	O
on	O
the	O
occurrence	O
of	O
AF	B-DS
or	O
vice	O
versa	O
.	O

However	O
,	O
we	O
obtained	O
a	O
significant	O
increase	O
of	O
the	O
right	O
atrial	O
area	O
and	O
mean	O
right	O
atrial	O
pressure	O
in	O
PH	B-DS
with	O
versus	O
without	O
AF	B-DS
(	O
figure	O
2	O
,	O
table	O
3	O
).	O

Moreover	O
,	O
right	O
ventricular	O
function	O
assessed	O
by	O
TAPSE	O
was	O
significantly	O
reduced	O
in	O
PH	B-DS
-	O
AF	B-DS
.	O

Consistently	O
,	O
cardiac	O
output	O
was	O
lower	O
in	O
the	O
PH	B-DS
-	O
AF	B-DS
group	O
compared	O
to	O
the	O
PH	B-DS
-	O
SR	O
group	O
(	O
table	O
3	O
).	O

A	O
comparison	O
of	O
patients	O
with	O
paroxysmal	O
(	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
)	O
and	O
chronic	O
(	O
PH	B-DS
-	O
AF	B-DS
chronic	O
)	O
AF	B-DS
in	O
PH	B-DS
indicated	O
increased	O
right	O
atrial	O
area	O
and	O
mean	O
right	O
atrial	O
pressure	O
in	O
patients	O
with	O
chronic	B-DS
AF	I-DS
versus	O
paroxysmal	B-DS
AF	I-DS
(	O
PH	B-DS
-	O
AF	B-DS
paroxysmal	I-DS
25	O
.	O
04	O
±	O
1	O
.	O
46	O
mm2	O
and	O
10	O
.	O
69	O
±	O
0	O
.	O
98	O
mmHg	O
vs	O
.	O
PH	B-DS
-	O
AF	B-DS
chronic	O
30	O
.	O
93	O
±	O
1	O
.	O
36	O
mm2	O
and	O
14	O
.	O
91	O
±	O
1	O
.	O
03	O
mmHg	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

AF	B-DS
in	O
PH	B-DS
not	O
related	O
to	O
left	O
heart	B-DS
disease	I-DS

Given	O
the	O
distinct	O
pathopyhsiology	O
of	O
pre	O
-	O
versus	O
postcapillary	O
PH	B-DS
,	O
in	O
a	O
subanalysis	O
patients	O
with	O
PH	B-DS
due	O
to	O
left	O
heart	B-DS
disease	I-DS
(	O
PH	B-DS
-	O
HF	B-DS
,	O
group	O
2	O
)	O
were	O
separated	O
from	O
patients	O
with	O
PH	B-DS
due	O
to	O
any	O
other	O
cause	O
(	O
PH	B-DS
-	O
nonHF	O
,	O
groups	O
1	O
,	O
3	O
,	O
4	O
,	O
or	O
5	O
).	O

In	O
PH	B-DS
not	O
related	O
to	O
left	O
heart	B-DS
disease	I-DS
,	O
AF	B-DS
was	O
observed	O
in	O
23	O
.	O
1	O
%	O
(	O
table	O
4	O
).	O

In	O
PAH	B-DS
(	O
group	O
1	O
)	O
AF	B-DS
was	O
found	O
in	O
29	O
.	O
1	O
%	O
(	O
table	O
5	O
).	O

AF	B-DS
was	O
associated	O
with	O
clinical	O
deterioration	O
,	O
as	O
indicated	O
by	O
a	O
higher	O
NYHA	O
/	O
WHO	O
functional	O
class	O
,	O
shorter	O
6	O
-	O
minute	O
walk	O
distance	O
,	O
more	O
severely	O
elevated	O
NT	B-GP
-	I-GP
proBNP	I-GP
serum	O
levels	O
and	O
compromised	O
renal	O
function	O
compared	O
to	O
patients	O
in	O
SR	O
(	O
table	O
4	O
,	O
table	O
5	O
).	O

Comparison	O
of	O
subgroups	O
with	O
SR	O
vs	O
.	O
AF	B-DS
in	O
PH	B-DS
not	O
related	O
to	O
left	O
heart	B-DS
disease	I-DS
(	O
nonHF	O
).	O

PH	B-DS
-	O
SR	O
nonHF	O

PH	B-DS
-	O
AF	B-DS
nonHF	O

Echocardiography	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

Left	O
atrial	O
diameter	O
[	O
mm	O
]	O

132	O

37	O
.	O
05	O
±	O
0	O
.	O
68	O

39	O

43	O
.	O
31	O
±	O
1	O
.	O
55	O
*	O

Right	O
atrial	O
area	O
[	O
mm2	O
]	O

132	O

23	O
.	O
53	O
±	O
0	O
.	O
66	O

38	O

30	O
.	O
51	O
±	O
1	O
.	O
61	O
*	O

TAPSE	O
[	O
mm	O
]	O

132	O

20	O
.	O
74	O
±	O
0	O
.	O
52	O

38	O

18	O
.	O
35	O
±	O
0	O
.	O
87	O
*	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

132	O

66	O
.	O
67	O
±	O
1	O
.	O
98	O

39	O

65	O
.	O
72	O
±	O
3	O
.	O
15	O

Left	O
ventricular	O
ejection	O
fraction	O
[%]	O

132	O

64	O
.	O
52	O
±	O
0	O
.	O
43	O

40	O

64	O
.	O
30	O
±	O
1	O
.	O
16	O

Right	O
heart	O
catheterization	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

133	O

67	O
.	O
02	O
±	O
2	O
.	O
04	O

40	O

68	O
.	O
25	O
±	O
3	O
.	O
24	O

Mean	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

133	O

41	O
.	O
25	O
±	O
1	O
.	O
23	O

40	O

40	O
.	O
38	O
±	O
2	O
.	O
04	O

Mean	O
right	O
atrial	O
pressure	O
[	O
mmHg	O
]	O

115	O

8	O
.	O
93	O
±	O
0	O
.	O
45	O

36	O

11	O
.	O
03	O
±	O
0	O
.	O
63	O
*	O

PCWP	O
[	O
mmHg	O
]	O

133	O

10	O
.	O
86	O
±	O
0	O
.	O
30	O

40	O

12	O
.	O
35	O
±	O
0	O
.	O
63	O

Pulmonary	O
vascular	O
resistance	O
[	O
Wood	O
units	O
]	O

126	O

7	O
.	O
74	O
±	O
0	O
.	O
46	O

38	O

7	O
.	O
16	O
±	O
0	O
.	O
75	O

Cardiac	O
output	O
[	O
l	O
/	O
min	O
]	O

111	O

4	O
.	O
36	O
±	O
0	O
.	O
13	O

25	O

3	O
.	O
94	O
±	O
0	O
.	O
19	O

Laboratory	O
parameters	O

NT	B-GP
-	I-GP
proBNP	I-GP
[	O
pg	O
/	O
l	O
]	O

133	O

1738	O
.	O
86	O
±	O
212	O
.	O
05	O

40	O

3449	O
.	O
40	O
±	O
547	O
.	O
61	O
*	O

Creatinine	O
[	O
mg	O
/	O
dl	O
]	O

133	O

1	O
.	O
06	O
±	O
0	O
.	O
03	O

40	O

1	O
.	O
23	O
±	O
0	O
.	O
08	O
*	O

Urea	O
nitrogen	O
[	O
mg	O
/	O
dl	O
]	O

133	O

48	O
.	O
23	O
±	O
2	O
.	O
10	O

40	O

64	O
.	O
40	O
±	O
5	O
.	O
39	O
*	O

eGFR	O
[	O
ml	O
/	O
min	O
//	O
1	O
.	O
72	O
m2	O
]	O

133	O

70	O
.	O
78	O
±	O
2	O
.	O
34	O

40	O

58	O
.	O
18	O
±	O
3	O
.	O
51	O
*	O

NYHA	O
classification	O

NYHA	O
I	O

1	O

0	O
.	O
8	O
%	O

0	O

0	O
%#	O

NYHA	O
II	O

51	O

38	O
.	O
3	O
%	O

8	O

20	O
.	O
0	O
%#	O

NYHA	O
III	O

78	O

58	O
.	O
6	O
%	O

31	O

77	O
.	O
5	O
%#	O

NYHA	O
IV	O

3	O

2	O
.	O
3	O
%	O

1	O

2	O
.	O
5	O
%#	O

6	O
-	O
minute	O
walk	O
test	O

6	O
-	O
minute	O
walk	O
test	O
[	O
m	O
]	O

113	O

364	O
.	O
67	O
±	O
10	O
.	O
51	O

31	O

303	O
.	O
87	O
±	O
17	O
.	O
36	O
*	O

Renal	O
function	O

CKD	B-DS
class	O
I	O

28	O

21	O
.	O
1	O
%	O

2	O

5	O
.	O
0	O
%#	O

CKD	B-DS
class	O
II	O

56	O

42	O
.	O
1	O
%	O

15	O

37	O
.	O
5	O
%#	O

CKD	B-DS
class	O
III	O

43	O

32	O
.	O
3	O
%	O

20	O

50	O
.	O
0	O
%#	O

CKD	B-DS
class	O
IV	O

6	O

4	O
.	O
5	O
%	O

3	O

7	O
.	O
5	O
%#	O

CKD	B-DS
class	O
V	O

0	O

0	O
%	O

0	O

0	O
%#	O

CKD	B-DS
=	O
Chronic	B-DS
kidney	I-DS
disease	I-DS
classification	O
,	O
eGFR	O
=	O
estimated	O
glomerular	O
filtration	O
rate	O
.	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
(	O
student	O
t	O
-	O
test	O
).	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
(	O
Mann	O
-	O
Whitney	O
test	O
).	O

Comparison	O
of	O
subgroups	O
with	O
SR	O
vs	O
.	O
AF	B-DS
in	O
PAH	B-DS
.	O

PAH	B-DS
-	O
SR	O

PAH	B-DS
-	O
AF	B-DS

Echocardiography	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

Left	O
atrial	O
diameter	O
[	O
mm	O
]	O

77	O

37	O
.	O
04	O
±	O
0	O
.	O
81	O

31	O

43	O
.	O
61	O
±	O
1	O
.	O
53	O
*	O

Right	O
atrial	O
area	O
[	O
mm2	O
]	O

77	O

22	O
.	O
92	O
±	O
0	O
.	O
87	O

31	O

31	O
.	O
33	O
±	O
1	O
.	O
49	O
*	O

TAPSE	O
[	O
mm	O
]	O

77	O

20	O
.	O
99	O
±	O
0	O
.	O
65	O

31	O

17	O
.	O
74	O
±	O
0	O
.	O
94	O
*	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

77	O

62	O
.	O
83	O
±	O
2	O
.	O
62	O

31	O

66	O
.	O
58	O
±	O
3	O
.	O
38	O

Left	O
ventricular	O
ejection	O
fraction	O
[%]	O

77	O

64	O
.	O
49	O
±	O
0	O
.	O
49	O

32	O

64	O
.	O
06	O
±	O
1	O
.	O
40	O

Right	O
heart	O
catheterization	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

78	O

65	O
.	O
27	O
±	O
2	O
.	O
31	O

32	O

70	O
.	O
03	O
±	O
3	O
.	O
83	O

Mean	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

78	O

41	O
.	O
22	O
±	O
1	O
.	O
73	O

32	O

41	O
.	O
47	O
±	O
2	O
.	O
45	O

Mean	O
right	O
atrial	O
pressure	O
[	O
mmHg	O
]	O

66	O

8	O
.	O
90	O
±	O
0	O
.	O
49	O

32	O

11	O
.	O
43	O
±	O
0	O
.	O
65	O
*	O

PCWP	O
[	O
mmHg	O
]	O

78	O

10	O
.	O
53	O
±	O
0	O
.	O
38	O

32	O

12	O
.	O
84	O
±	O
0	O
.	O
63	O

Pulmonary	O
vascular	O
resistance	O
[	O
Wood	O
units	O
]	O

74	O

7	O
.	O
49	O
±	O
0	O
.	O
60	O

32	O

7	O
.	O
58	O
±	O
0	O
.	O
87	O

Cardiac	O
output	O
[	O
l	O
/	O
min	O
]	O

66	O

4	O
.	O
41	O
±	O
0	O
.	O
19	O

21	O

3	O
.	O
98	O
±	O
0	O
.	O
26	O

Laboratory	O
parameters	O

NT	B-GP
-	I-GP
proBNP	I-GP
[	O
pg	O
/	O
l	O
]	O

78	O

1705	O
.	O
81	O
±	O
232	O
.	O
49	O

32	O

3529	O
.	O
84	O
±	O
537	O
.	O
77	O
*	O

Creatinine	O
[	O
mg	O
/	O
dl	O
]	O

78	O

1	O
.	O
06	O
±	O
0	O
.	O
04	O

32	O

1	O
.	O
38	O
±	O
0	O
.	O
09	O
*	O

Urea	O
nitrogen	O
[	O
mg	O
/	O
dl	O
]	O

78	O

45	O
.	O
98	O
±	O
2	O
.	O
38	O

32	O

68	O
.	O
19	O
±	O
4	O
.	O
55	O
*	O

eGFR	O
[	O
ml	O
/	O
min	O
//	O
1	O
.	O
72	O
m2	O
]	O

78	O

73	O
.	O
76	O
±	O
3	O
.	O
47	O

32	O

59	O
.	O
09	O
±	O
3	O
.	O
09	O
*	O

NYHA	O
classification	O

NYHA	O
I	O

1	O

1	O
.	O
3	O
%	O

0	O

0	O
%#	O

NYHA	O
II	O

35	O

44	O
.	O
9	O
%	O

7	O

21	O
.	O
9	O
%#	O

NYHA	O
III	O

41	O

52	O
.	O
6	O
%	O

24	O

75	O
.	O
0	O
%#	O

NYHA	O
IV	O

1	O

1	O
.	O
3	O
%	O

1	O

3	O
.	O
1	O
%#	O

6	O
-	O
minute	O
walk	O
test	O

6	O
-	O
minute	O
walk	O
test	O
[	O
m	O
]	O

66	O

384	O
.	O
21	O
±	O
11	O
.	O
67	O

26	O

311	O
.	O
35	O
±	O
18	O
.	O
04	O
*	O

Renal	O
function	O

CKD	B-DS
class	O
I	O

20	O

25	O
.	O
6	O
%	O

2	O

6	O
.	O
3	O
%#	O

CKD	B-DS
class	O
II	O

30	O

38	O
.	O
5	O
%	O

13	O

40	O
.	O
6	O
%#	O

CKD	B-DS
class	O
III	O

24	O

30	O
.	O
8	O
%	O

15	O

46	O
.	O
9	O
%#	O

CKD	B-DS
class	O
IV	O

4	O

5	O
.	O
1	O
%	O

2	O

6	O
.	O
3	O
%#	O

CKD	B-DS
class	O
V	O

0	O

0	O
%	O

0	O

0	O
%#	O

CKD	B-DS
=	O
Chronic	B-DS
kidney	I-DS
disease	I-DS
classification	O
,	O
eGFR	O
=	O
estimated	O
glomerular	O
filtration	O
rate	O
.	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PAH	B-DS
-	O
SR	O
(	O
student	O
t	O
-	O
test	O
).	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PAH	B-DS
-	O
SR	O
(	O
Mann	O
-	O
Whitney	O
test	O
).	O

While	O
consistent	O
with	O
the	O
total	O
PH	B-DS
cohort	O
,	O
no	O
difference	O
of	O
systolic	O
and	O
mean	O
pulmonary	O
arterial	O
pressures	O
in	O
the	O
presence	O
or	O
absence	O
of	O
AF	B-DS
was	O
obtained	O
;	O
increased	O
right	O
atrial	O
pressure	O
and	O
size	O
as	O
well	O
as	O
reduced	O
right	O
ventricular	O
function	O
were	O
the	O
most	O
obvious	O
hemodynamic	O
differences	O
between	O
prevalent	O
AF	B-DS
versus	O
no	O
AF	B-DS
in	O
PH	B-DS
-	O
nonHF	O
and	O
PAH	B-DS
.	O

As	O
expected	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
PCWP	O
were	O
similar	O
in	O
both	O
groups	O
(	O
table	O
4	O
,	O
table	O
5	O
).	O

AF	B-DS
in	O
left	O
heart	B-DS
disease	I-DS
with	O
PH	B-DS

In	O
patients	O
with	O
PH	B-DS
due	O
to	O
left	O
heart	B-DS
disease	I-DS
,	O
AF	B-DS
was	O
prevalent	O
in	O
57	O
.	O
7	O
%.	O

While	O
AF	B-DS
in	O
this	O
cohort	O
did	O
not	O
further	O
diminish	O
exercise	O
capacity	O
or	O
NYHA	O
/	O
WHO	O
functional	O
class	O
,	O
we	O
still	O
observed	O
higher	O
NT	B-GP
-	I-GP
proBNP	I-GP
values	O
and	O
more	O
severely	O
compromised	O
renal	O
function	O
in	O
those	O
patients	O
with	O
AF	B-DS
versus	O
SR	O
(	O
table	O
6	O
).	O

Comparison	O
of	O
subgroups	O
with	O
SR	O
vs	O
.	O
AF	B-DS
in	O
PH	B-DS
related	O
to	O
left	O
heart	B-DS
disease	I-DS
(	O
HF	B-DS
).	O

PH	B-DS
-	O
SR	O
HF	B-DS

PH	B-DS
-	O
AF	B-DS
HF	B-DS

Echocardiography	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

n	O

%	O
or	O
Mean	O
±	O
SEM	O

Left	O
atrial	O
diameter	O
[	O
mm	O
]	O

22	O

37	O
.	O
36	O
±	O
1	O
.	O
89	O

30	O

49	O
.	O
87	O
±	O
1	O
.	O
96	O
*	O

Right	O
atrial	O
area	O
[	O
mm2	O
]	O

22	O

20	O
.	O
87	O
±	O
1	O
.	O
65	O

30	O

26	O
.	O
17	O
±	O
1	O
.	O
69	O
*	O

TAPSE	O
[	O
mm	O
]	O

22	O

22	O
.	O
32	O
±	O
1	O
.	O
25	O

29	O

17	O
.	O
45	O
±	O
0	O
.	O
94	O
*	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

22	O

52	O
.	O
14	O
±	O
3	O
.	O
75	O

30	O

52	O
.	O
80	O
±	O
2	O
.	O
34	O

Left	O
ventricular	O
ejection	O
fraction	O
[%]	O

22	O

59	O
.	O
55	O
±	O
2	O
.	O
69	O

29	O

53	O
.	O
69	O
±	O
2	O
.	O
90	O

Right	O
heart	O
catheterization	O

Systolic	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

22	O

52	O
.	O
86	O
±	O
3	O
.	O
29	O

30	O

64	O
.	O
10	O
±	O
3	O
.	O
36	O
*	O

Mean	O
pulmonary	O
artery	O
pressure	O
[	O
mmHg	O
]	O

22	O

34	O
.	O
23	O
±	O
2	O
.	O
01	O

30	O

41	O
.	O
37	O
±	O
2	O
.	O
46	O
*	O

Mean	O
right	O
atrial	O
pressure	O
[	O
mmHg	O
]	O

20	O

12	O
.	O
10	O
±	O
1	O
.	O
16	O

25	O

16	O
.	O
92	O
±	O
1	O
.	O
37	O
*	O

PCWP	O
[	O
mmHg	O
]	O

22	O

18	O
.	O
63	O
±	O
1	O
.	O
21	O

30	O

22	O
.	O
13	O
±	O
1	O
.	O
37	O

Pulmonary	O
vascular	O
resistance	O
[	O
Wood	O
units	O
]	O

20	O

4	O
.	O
48	O
±	O
0	O
.	O
77	O

28	O

5	O
.	O
50	O
±	O
0	O
.	O
77	O

Cardiac	O
output	O
[	O
l	O
/	O
min	O
]	O

16	O

4	O
.	O
33	O
±	O
0	O
.	O
26	O

22	O

3	O
.	O
89	O
±	O
0	O
.	O
28	O

Laboratory	O
parameters	O

NT	B-GP
-	I-GP
proBNP	I-GP
[	O
pg	O
/	O
l	O
]	O

22	O

1149	O
.	O
00	O
±	O
181	O
.	O
61	O

30	O

3257	O
.	O
30	O
±	O
568	O
.	O
65	O
*	O

Creatinine	O
[	O
mg	O
/	O
dl	O
]	O

21	O

1	O
.	O
11	O
±	O
0	O
.	O
06	O

29	O

1	O
.	O
58	O
±	O
0	O
.	O
25	O
*	O

Urea	O
nitrogen	O
[	O
mg	O
/	O
dl	O
]	O

21	O

55	O
.	O
10	O
±	O
5	O
.	O
60	O

29	O

83	O
.	O
93	O
±	O
10	O
.	O
35	O
*	O

eGFR	O
[	O
ml	O
/	O
min	O
//	O
1	O
.	O
72	O
m2	O
]	O

21	O

62	O
.	O
71	O
±	O
4	O
.	O
27	O

29	O

50	O
.	O
52	O
±	O
3	O
.	O
97	O
*	O

NYHA	O
classification	O

NYHA	O
I	O

2	O

9	O
.	O
1	O
%	O

0	O

0	O
.	O
0	O
%	O

NYHA	O
II	O

4	O

18	O
.	O
2	O
%	O

11	O

36	O
.	O
7	O
%	O

NYHA	O
III	O

16	O

72	O
.	O
7	O
%	O

19	O

63	O
.	O
3	O
%	O

NYHA	O
IV	O

0	O

0	O
%	O

0	O

0	O
%	O

6	O
-	O
minute	O
walk	O
test	O

6	O
-	O
minute	O
walk	O
test	O
[	O
m	O
]	O

17	O

294	O
.	O
88	O
±	O
24	O
.	O
29	O

22	O

333	O
.	O
41	O
±	O
23	O
.	O
99	O

Renal	O
function	O

CKD	B-DS
class	O
I	O

3	O

13	O
.	O
6	O
%	O

1	O

3	O
.	O
3	O
%#	O

CKD	B-DS
class	O
II	O

8	O

36	O
.	O
4	O
%	O

8	O

26	O
.	O
7	O
%#	O

CKD	B-DS
class	O
III	O

10	O

45	O
.	O
5	O
%	O

15	O

50	O
.	O
0	O
%#	O

CKD	B-DS
class	O
IV	O

0	O

0	O
%	O

5	O

16	O
.	O
7	O
%#	O

CKD	B-DS
class	O
V	O

1	O

4	O
.	O
5	O
%	O

1	O

3	O
.	O
3	O
%#	O

CKD	B-DS
=	O
Chronic	B-DS
kidney	I-DS
disease	I-DS
classification	O
,	O
eGFR	O
=	O
estimated	O
glomerular	O
filtration	O
rate	O
.	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
(	O
student	O
t	O
-	O
test	O
).	O

p	O
<	O
0	O
.	O
05	O
vs	O
.	O
PH	B-DS
-	O
SR	O
(	O
Mann	O
-	O
Whitney	O
test	O
).	O

Left	O
atrial	O
size	O
was	O
significantly	O
larger	O
and	O
PCWP	O
tended	O
to	O
be	O
higher	O
in	O
prevalent	O
AF	B-DS
,	O
although	O
the	O
latter	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Invasive	O
measurements	O
demonstrated	O
increased	O
systolic	O
and	O
mean	O
pulmonary	O
arterial	O
and	O
right	O
atrial	O
pressures	O
associated	O
with	O
AF	B-DS
.	O

Moreover	O
,	O
echocardiography	O
indicated	O
right	O
heart	O
impairment	O
,	O
i	O
.	O
e	O
.	O
increased	O
right	O
atrial	O
area	O
and	O
suppressed	O
TAPSE	O
in	O
the	O
subgroup	O
with	O
prevalent	O
AF	B-DS
(	O
table	O
6	O
).	O

Discussion	O

Atrial	B-DS
fibrillation	I-DS
affects	O
1	O
–	O
2	O
%	O
of	O
the	O
general	O
population	O
.	O

The	O
prevalence	O
of	O
AF	B-DS
increases	O
with	O
age	O
,	O
from	O
0	O
.	O
5	O
%	O
at	O
40	O
–	O
50	O
years	O
,	O
to	O
5	O
–	O
15	O
%	O
at	O
80	O
years	O
[	O
19	O
].	O

Atrial	B-DS
fibrillation	I-DS
is	O
highly	O
prevalent	O
among	O
patients	O
with	O
left	B-DS
ventricular	I-DS
heart	I-DS
failure	I-DS
,	O
and	O
can	O
lead	O
to	O
adverse	O
consequences	O
,	O
including	O
tachycardia	O
-	O
related	O
cardiomyopathy	B-DS
,	O
reduction	O
in	O
left	O
ventricular	O
preload	O
attributable	O
to	O
disorganized	O
atrial	O
contractions	O
,	O
increased	O
risk	O
of	O
systemic	B-DS
embolism	I-DS
,	O
and	O
overall	O
poorer	O
long	O
-	O
term	O
outcome	O
[	O
20	O
],	O
[	O
21	O
],	O
[	O
22	O
].	O

Supraventricular	B-DS
tachyarrhythmias	I-DS
occurred	O
in	O
patients	O
with	O
pulmonary	B-DS
hypertension	I-DS
with	O
an	O
annual	O
incidence	O
of	O
2	O
.	O
8	O
%.	O

Atrial	B-DS
flutter	I-DS
and	O
atrial	B-DS
fibrillation	I-DS
were	O
equally	O
common	O
and	O
both	O
arrhythmias	O
led	O
to	O
acute	O
clinical	O
deterioration	O
with	O
signs	O
of	O
right	B-DS
heart	I-DS
failure	I-DS
,	O
while	O
only	O
atrial	B-DS
fibrillation	I-DS
exerted	O
an	O
impact	O
on	O
mortality	O
[	O
23	O
].	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
total	O
prevalence	O
of	O
AF	B-DS
in	O
patients	O
with	O
PH	B-DS
and	O
possible	O
differences	O
among	O
distinct	O
etiological	O
groups	O
of	O
PH	B-DS
have	O
not	O
been	O
defined	O
.	O

In	O
the	O
present	O
cohort	O
of	O
patients	O
with	O
confirmed	O
PH	B-DS
of	O
various	O
origins	O
,	O
we	O
found	O
that	O
AF	B-DS
affected	O
approximately	O
one	O
-	O
third	O
of	O
patients	O
.	O

Thus	O
,	O
the	O
prevalence	O
of	O
AF	B-DS
in	O
PH	B-DS
is	O
considerably	O
higher	O
than	O
in	O
the	O
normal	O
population	O
at	O
similar	O
age	O
[	O
24	O
].	O

This	O
was	O
also	O
true	O
for	O
all	O
PH	B-DS
subgroups	O
except	O
for	O
patients	O
with	O
chronic	B-DS
thromboembolic	I-DS
pulmonary	I-DS
hypertension	I-DS
(	O
CTEPH	B-DS
).	O

Particularly	O
,	O
more	O
than	O
half	O
of	O
the	O
patients	O
with	O
PH	B-DS
related	O
to	O
left	O
heart	B-DS
disease	I-DS
were	O
affected	O
by	O
AF	B-DS
.	O

Symptomatic	O
heart	B-DS
failure	I-DS
has	O
been	O
reported	O
in	O
30	O
%	O
of	O
AF	B-DS
patients	O
and	O
AF	B-DS
is	O
found	O
in	O
up	O
to	O
30	O
%	O
of	O
heart	B-DS
failure	I-DS
patients	O
,	O
depending	O
on	O
the	O
underlying	O
cause	O
and	O
severity	O
of	O
heart	B-DS
failure	I-DS
[	O
9	O
],	O
[	O
19	O
].	O

Pulmonary	B-DS
hypertension	I-DS
in	O
heart	B-DS
failure	I-DS
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
an	O
increased	O
severity	O
of	O
disease	O
[	O
5	O
].	O

Compared	O
to	O
the	O
cited	O
populations	O
mentioned	O
above	O
we	O
observed	O
a	O
significantly	O
higher	O
prevalence	O
of	O
AF	B-DS
in	O
patients	O
with	O
left	O
heart	B-DS
disease	I-DS
combined	O
with	O
PH	B-DS
(	O
57	O
.	O
7	O
%),	O
supporting	O
the	O
notion	O
that	O
our	O
patients	O
suffered	O
from	O
more	O
severe	O
heart	B-DS
failure	I-DS
,	O
which	O
was	O
also	O
indicated	O
by	O
the	O
high	O
prevalence	O
of	O
patients	O
with	O
NYHA	O
III	O
and	O
markedly	O
elevated	O
NT	B-GP
-	I-GP
proBNP	I-GP
levels	O
.	O

Moreover	O
,	O
these	O
data	O
suggest	O
that	O
more	O
advanced	O
heart	B-DS
failure	I-DS
leading	O
to	O
PH	B-DS
is	O
a	O
relevant	O
risk	O
factor	O
for	O
the	O
development	O
of	O
AF	B-DS
.	O

Given	O
the	O
retrospective	O
design	O
of	O
our	O
study	O
,	O
we	O
may	O
even	O
have	O
underestimated	O
the	O
true	O
prevalence	O
of	O
AF	B-DS
in	O
PH	B-DS
.	O

Diagnosis	O
of	O
AF	B-DS
was	O
made	O
by	O
carefully	O
analyzing	O
patient	O
'	O
s	O
history	O
and	O
standard	O
electrocardiograms	O
.	O

Because	O
of	O
the	O
lack	O
of	O
other	O
means	O
of	O
rhythm	O
monitoring	O
(	O
i	O
.	O
e	O
.	O
periodical	O
Holter	O
recordings	O
,	O
implanted	O
event	O
recorders	O
),	O
it	O
is	O
likely	O
that	O
some	O
self	O
-	O
limiting	O
silent	O
AF	B-DS
episodes	O
might	O
have	O
been	O
missed	O
.	O

When	O
analyzing	O
hemodynamic	O
factors	O
promoting	O
AF	B-DS
in	O
PH	B-DS
it	O
seems	O
plausible	O
to	O
separately	O
evaluate	O
patients	O
with	O
and	O
without	O
left	O
heart	B-DS
disease	I-DS
.	O

Previously	O
,	O
reduced	O
left	O
ventricular	O
function	O
,	O
elevated	O
end	O
-	O
diastolic	O
left	O
ventricular	O
pressure	O
and	O
,	O
thus	O
,	O
higher	O
PCWP	O
and	O
larger	O
left	O
atrial	O
diameter	O
have	O
been	O
associated	O
with	O
an	O
increased	O
propensity	O
of	O
AF	B-DS
in	O
left	O
heart	B-DS
disease	I-DS
.	O

Consistently	O
,	O
in	O
the	O
present	O
study	O
these	O
parameters	O
were	O
more	O
severely	O
altered	O
in	O
prevalent	O
AF	B-DS
than	O
in	O
patients	O
with	O
SR	O
.	O

Notably	O
,	O
in	O
PH	B-DS
-	O
HF	B-DS
with	O
AF	B-DS
we	O
observed	O
increased	O
pulmonary	O
artery	O
pressures	O
in	O
invasive	O
measurements	O
,	O
which	O
are	O
more	O
accurate	O
than	O
echocardiographic	O
estimation	O
[	O
25	O
],	O
and	O
signs	O
of	O
right	O
heart	O
impairment	O
,	O
indicating	O
that	O
AF	B-DS
in	O
PH	B-DS
related	O
to	O
left	O
heart	B-DS
disease	I-DS
was	O
associated	O
with	O
more	O
marked	O
backward	O
failure	O
compared	O
to	O
SR	O
.	O

Thus	O
far	O
,	O
hemodynamic	O
factors	O
that	O
might	O
contribute	O
to	O
onset	O
of	O
AF	B-DS
in	O
PH	B-DS
not	O
related	O
to	O
left	O
heart	B-DS
disease	I-DS
have	O
not	O
been	O
evaluated	O
.	O

In	O
the	O
present	O
analysis	O
,	O
elevated	O
right	O
atrial	O
pressure	O
and	O
right	B-DS
atrial	I-DS
dilatation	I-DS
were	O
the	O
most	O
prominent	O
parameters	O
associated	O
with	O
prevalent	O
AF	B-DS
in	O
PH	B-DS
-	O
nonHF	O
.	O

While	O
systolic	O
and	O
mean	O
pulmonary	O
pressures	O
did	O
not	O
directly	O
correlate	O
with	O
AF	B-DS
occurrence	O
in	O
nonHF	O
patients	O
,	O
the	O
severity	O
of	O
pulmonary	B-DS
hypertension	I-DS
might	O
have	O
been	O
masked	O
by	O
impairment	O
of	O
right	O
ventricular	O
function	O
,	O
thus	O
rather	O
supporting	O
the	O
notion	O
that	O
AF	B-DS
is	O
more	O
common	O
in	O
more	O
advanced	O
PH	B-DS
.	O

These	O
results	O
provide	O
insight	O
into	O
the	O
possible	O
pathophysiology	O
of	O
AF	B-DS
in	O
PH	B-DS
and	O
indicate	O
a	O
different	O
pathomechanism	O
of	O
AF	B-DS
induction	O
in	O
PH	B-DS
with	O
versus	O
without	O
left	O
heart	B-DS
disease	I-DS
.	O

In	O
the	O
absence	O
of	O
left	O
heart	B-DS
disease	I-DS
(	O
i	O
)	O
left	O
atrial	O
pressure	O
does	O
not	O
play	O
a	O
pathophysiological	O
role	O
and	O
(	O
ii	O
)	O
pulmonary	O
artery	O
pressure	O
does	O
not	O
seem	O
to	O
provoke	O
AF	B-DS
by	O
itself	O
,	O
but	O
an	O
increase	O
in	O
right	O
atrial	O
pressure	O
leading	O
to	O
right	B-DS
atrial	I-DS
dilatation	I-DS
seems	O
to	O
be	O
responsible	O
for	O
onset	O
of	O
AF	B-DS
.	O

There	O
is	O
only	O
limited	O
data	O
available	O
regarding	O
the	O
clinical	O
consequences	O
of	O
AF	B-DS
in	O
patients	O
with	O
various	O
forms	O
of	O
PH	B-DS
.	O

Previous	O
studies	O
indicated	O
that	O
elevated	O
heart	O
rate	O
might	O
lead	O
to	O
increased	O
mortality	O
in	O
patients	O
suffering	O
from	O
PH	B-DS
.	O

Notably	O
,	O
mean	O
heart	O
frequency	O
in	O
PH	B-DS
-	O
AF	B-DS
was	O
not	O
significantly	O
different	O
compared	O
to	O
PH	B-DS
-	O
SR	O
in	O
our	O
population	O
.	O

The	O
influence	O
of	O
AF	B-DS
on	O
clinical	O
performance	O
and	O
cardiac	O
function	O
in	O
PH	B-DS
has	O
not	O
been	O
investigated	O
yet	O
.	O

In	O
our	O
cohort	O
patients	O
with	O
PH	B-DS
-	O
AF	B-DS
demonstrated	O
significant	O
impairment	O
in	O
NYHA	O
/	O
WHO	O
functional	O
class	O
and	O
6	O
-	O
minute	O
walk	O
distance	O
compared	O
to	O
PH	B-DS
-	O
SR	O
.	O

This	O
clinical	O
deterioration	O
in	O
the	O
presence	O
of	O
AF	B-DS
was	O
also	O
evident	O
by	O
the	O
higher	O
prescription	O
rate	O
of	O
diuretics	O
.	O

Elevation	O
of	O
NT	B-GP
-	I-GP
proBNP	I-GP
as	O
a	O
marker	O
for	O
heart	B-DS
failure	I-DS
and	O
renal	B-DS
insufficiency	I-DS
have	O
been	O
implicated	O
to	O
correlate	O
with	O
prognosis	O
and	O
severity	O
of	O
disease	O
in	O
PH	B-DS
.	O

In	O
the	O
present	O
study	O
these	O
laboratory	O
parameters	O
were	O
consistently	O
increased	O
in	O
the	O
total	O
PH	B-DS
population	O
and	O
in	O
all	O
subgroups	O
with	O
prevalent	O
AF	B-DS
compared	O
to	O
SR	O
,	O
further	O
supporting	O
the	O
notion	O
that	O
AF	B-DS
in	O
PH	B-DS
is	O
associated	O
with	O
more	O
advanced	O
compromise	O
of	O
hemodynamic	O
function	O
.	O

Recently	O
,	O
renal	B-DS
failure	I-DS
,	O
reduced	O
6	O
-	O
minute	O
walk	O
distance	O
,	O
elevated	O
mean	O
right	O
atrial	O
pressure	O
,	O
and	O
increased	O
brain	B-GP
natriuretic	I-GP
peptide	I-GP
have	O
been	O
suggested	O
as	O
independent	O
predictors	O
of	O
mortality	O
in	O
PH	B-DS
.	O

Therefore	O
,	O
it	O
remains	O
to	O
be	O
determined	O
in	O
a	O
larger	O
prospective	O
study	O
whether	O
AF	B-DS
in	O
PH	B-DS
is	O
just	O
a	O
marker	O
of	O
more	O
advanced	O
disease	O
,	O
is	O
an	O
independent	O
risk	O
factor	O
,	O
and	O
/	O
or	O
if	O
cardioversion	O
might	O
improve	O
symptoms	O
,	O
exercise	O
capacity	O
and	O
possibly	O
prognosis	O
in	O
this	O
population	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

